Last reviewed · How we verify

NCT05691322: ValDEVA

Prospective Validation of the DEVA Algorithm for the Prediction of Severe Endometriosis

Status unknown Last updated 20 January 2023
What this trial tests

trial testing transvaginal ultrasound in Endometriosis in 276 participants. Status unknown.

Timeline
19 October 2022
Primary endpoint
19 October 2023
19 January 2024

Quick facts

Lead sponsorOne Clinic
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment276
Start date19 October 2022
Primary completion19 October 2023
Estimated completion19 January 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

One Clinic

Who can join

Adults 18 to 45, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Endometriosis is a chronic disease affecting 1 in 10 women. Its diagnosis is difficult and the time between the first symptoms and diagnosis is of about 7 years. diagnosis requires specialized imaging performed by referral practitioners for this pathology. According to current recommendations, non-specialized pelvic ultrasound is the recommended first-line examination. However, only reference ultrasound, performed by a doctor specialized in the disease and carried out according to a specific protocol (such as UBESS), is sufficiently reliable for diagnosis. The number of practitioners performing this type of examination is very low in France, which in practice results in a very low reliability of this strategy in real life. Pelvic MRI is also a much more reliable examination, available for review. However its access is limited. In addition, the false positive rate can be as high as 20%, particularly for minor forms of the disease. The DEVA algorithm has been developed for the identification of women with endometriosis based on a self-administered pelvic pain symptom questionnaire (ENDOPAIN). In a preliminary study, this algorithm seems reliable for identify patients at high risk of this disease and would thus allow to triage patients requiring patients requiring an immediate MRI in order to shorten diagnostic delays. External validation of the algorithm is therefore necessary before clinical use. The main objective od this study is the prospective external validation of the diagnostic reliability of the DEVA algorithm used for the detection of women with endometriosis (visible on MRI or transvaginal ultrasound).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of transvaginal ultrasound

Trials testing the same drug.

Other recruiting trials for Endometriosis

Currently open trials in the same condition.

Other One Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05691322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing